サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1571951

乳がんリキッドバイオプシーの世界市場

Breast Cancer Liquid Biopsy

出版日
ページ情報
英文 89 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.82円
乳がんリキッドバイオプシーの世界市場
出版日: 2024年10月18日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 89 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

乳がんリキッドバイオプシーの世界市場は2030年までに11億米ドルに達する見込み

2023年に2億7,790万米ドルと推定された乳がんリキッドバイオプシーの世界市場は、分析期間2023-2030年にCAGR 21.4%で成長し、2030年には11億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである試薬キットは、CAGR 22.0％を記録し、分析期間終了時には8億1,930万米ドルに達すると予測されます。機器セグメントの成長率は、分析期間中CAGR 21.0％と推定されます。

米国市場は7,700万米ドルと推定、中国はCAGR20.4％で成長予測

米国の乳がんリキッドバイオプシー市場は、2023年に7,700万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに1億6,140万米ドルの市場規模に達すると予測され、分析期間2023-2030年のCAGRは20.4%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ19.0％と18.4％と予測されています。欧州では、ドイツがCAGR約15.8%で成長すると予測されています。

世界の乳がんリキッドバイオプシー市場- 主要動向と促進要因まとめ

リキッドバイオプシーは乳がんの診断と治療にどのような変革をもたらすか？

リキッドバイオプシーは、循環腫瘍細胞（CTC）、循環腫瘍DNA（ctDNA）、および血液やその他の体液中に存在するその他のバイオマーカーの分析を通じて、がんを検出およびモニタリングするための低侵襲な方法を提供することにより、乳がんの診断と治療に革命をもたらしています。従来、乳がんの診断は、外科的に腫瘍のサンプルを採取して分析する組織生検に大きく依存していました。リキッドバイオプシーは、より侵襲性の低い代替法を提供し、手術を必要とせずに、遺伝子変異、治療抵抗性、腫瘍の進行の頻繁なモニタリングと早期発見を可能にします。これは、健康状態や腫瘍の位置のために侵襲的な処置を繰り返すことができない患者にとって特に有益です。

リキッドバイオプシー技術の重要な進歩のひとつは、がんの分子プロファイルに関する洞察をリアルタイムで提供し、個別化治療戦略を可能にする能力です。ctDNAやCTCを分析することにより、腫瘍医は、HER2やBRCA変異のような、がんを進行させている特定の遺伝子変異を同定することができ、標的療法の選択の指針とすることができます。さらに、リキッドバイオプシーによって治療効果を継続的にモニタリングできるため、医師は薬剤耐性を早期に発見し、それに応じて治療計画を調整することができます。このプレシジョン・メディシン・アプローチは、患者により個別化され、効果的で、適応性のある治療選択肢を提供することにより、乳がん治療を変革しています。

乳がんの早期発見とモニタリングにおいてリキッドバイオプシーはどのような役割を果たすのか？

リキッドバイオプシーは、乳がんの早期発見とモニタリングにおいて、臨床医が画像診断や身体検査で検出可能になる前にがん変異や腫瘍動態の変化を同定できるようにすることで、重要な役割を果たしています。早期乳がんは無症状であることが多く、マンモグラムや組織生検などの従来の診断方法では、小さな病変や初期の病変を見逃してしまうことがあります。しかし、リキッドバイオプシーは、腫瘍から血流に排出される微量のctDNAを検出することができ、がんを早期に発見する非侵襲的な方法を提供します。早期発見は治療成功の可能性を高め、転移のリスクを低減するため、患者の予後を改善するために極めて重要です。

早期発見だけでなく、リキッドバイオプシーは、乳がん患者のペイシェントジャーニーを通じた継続的モニタリングにも有用です。ctDNAまたはCTCレベルの変化を追跡することで、臨床医は患者が治療にどの程度反応しているかを評価し、微小残存病変（MRD）を検出し、従来の画像診断法で腫瘍の増大が明らかになる前に再発の徴候を特定することができます。がんの進行をリアルタイムでモニターするこの能力は、よりダイナミックで個別化された治療計画を可能にし、全生存率を向上させ、より侵襲的な検査の必要性を減らします。リキッドバイオプシー技術が進化し続けるにつれて、乳がんの早期発見と患者の長期モニタリングの両方において標準的なツールになることが期待されます。

リキッドバイオプシーは乳がんの個別化医療をどのように進めているのか？

リキッドバイオプシーは、各患者の腫瘍の遺伝的および分子的状況をより深く理解することを可能にすることにより、乳がんにおける個別化医療を前進させる最前線にあります。ctDNAの解析を通じて、リキッドバイオプシーはPIK3CA、ESR1、BRCA1/2などの特定の遺伝子変異を同定することができます。この情報により、腫瘍医は個々の患者固有のがんプロファイルに合わせた治療を行うことができ、実用的な変異の存在に基づいて最も効果が期待できる治療を選択することができます。例えば、HER2陽性乳がん患者はトラスツズマブのような標的治療薬が有効であり、BRCA変異を有する患者はPARP阻害薬がよりよく反応する可能性があります。

リキッドバイオプシーはまた、乳がん管理における共通の課題である治療抵抗性の出現を特定するのにも役立ちます。時間の経過とともに、がん細胞は化学療法や標的療法の効果を回避するための新たな変異を獲得する可能性があります。リキッドバイオプシーによって、臨床医はこのような耐性変異を早期に発見することができ、がんがさらに進行する前に治療戦略を調整したり、代替療法に切り替えたりできる可能性があります。リキッドバイオプシーは、腫瘍の進展に関する分子レベルの洞察をリアルタイムで提供することで、乳がん患者の治療効果を最適化し、不必要な副作用を最小限に抑える個別化医療のアプローチを後押ししています。

乳がんリキッドバイオプシー市場の成長を促進する要因は何か？

乳がんリキッドバイオプシー市場の成長は、非侵襲的診断法に対する需要の増加、精密医療の進歩、世界の乳がん罹患率の上昇など、いくつかの重要な要因によってもたらされます。リキッドバイオプシーは組織生検に代わる、より安全で侵襲性の低い方法を提供するため、特に頻繁なモニタリングが必要な患者や従来の生検の候補とならない患者に対して、このアプローチを選択する患者やヘルスケアプロバイダーが増えています。治療期間中に繰り返しリキッドバイオプシーを実施できることから、疾患の進行を継続的にモニタリングすることも可能となり、患者の転帰の改善に役立ちます。

次世代シーケンシング（NGS）やデジタルPCRなどのリキッドバイオプシー・プラットフォームの技術的進歩は、これらの検査の感度と精度を高め、市場の採用をさらに促進しています。リキッドバイオプシーは個々の患者に合わせた治療に必要な分子的洞察を提供するため、個別化医療と標的治療への注目の高まりも市場成長を促す主要因となっています。さらに、世界の乳がん罹患率の増加により、早期発見・モニタリングツールに対する需要が高まっており、リキッドバイオプシー市場の拡大に寄与しています。ヘルスケアシステムが精密腫瘍学と非侵襲的診断をますます優先するようになるにつれて、乳がんリキッドバイオプシー市場は今後数年間で持続的な成長が見込まれます。

調査対象企業の例（注目の34社）

  • Biodesix, Inc.
  • Bio-Rad Laboratories
  • Cynvenio Biosystems, Inc.
  • Fluxion Biosciences, Inc.
  • Genomic Health, Inc.
  • Guardant Health, Inc.
  • Illumina
  • Isogen Life Science B.V.
  • Menarini Silicon Biosystems
  • Myriad Genetics

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP21384

Global Breast Cancer Liquid Biopsy Market to Reach US$1.1 Billion by 2030

The global market for Breast Cancer Liquid Biopsy estimated at US$277.9 Million in the year 2023, is expected to reach US$1.1 Billion by 2030, growing at a CAGR of 21.4% over the analysis period 2023-2030. Reagent Kits, one of the segments analyzed in the report, is expected to record a 22.0% CAGR and reach US$819.3 Million by the end of the analysis period. Growth in the Instruments segment is estimated at 21.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$77.0 Million While China is Forecast to Grow at 20.4% CAGR

The Breast Cancer Liquid Biopsy market in the U.S. is estimated at US$77.0 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$161.4 Million by the year 2030 trailing a CAGR of 20.4% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 19.0% and 18.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 15.8% CAGR.

Global Breast Cancer Liquid Biopsy Market – Key Trends & Drivers Summarized

How Are Liquid Biopsies Transforming Breast Cancer Diagnosis and Treatment?

Liquid biopsies are revolutionizing breast cancer diagnosis and treatment by providing a minimally invasive method for detecting and monitoring cancer through the analysis of circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), and other biomarkers present in blood or other bodily fluids. Traditionally, breast cancer diagnosis relied heavily on tissue biopsies, which involve surgically removing a sample of the tumor for analysis. Liquid biopsies offer a less invasive alternative, allowing for frequent monitoring and early detection of genetic mutations, treatment resistance, and tumor progression without the need for surgery. This is particularly beneficial for patients who cannot undergo repeated invasive procedures due to health conditions or the location of the tumor.

One of the key advancements in liquid biopsy technology is its ability to provide real-time insights into the molecular profile of the cancer, enabling personalized treatment strategies. By analyzing ctDNA and CTCs, oncologists can identify specific genetic mutations driving the cancer, such as HER2 or BRCA mutations, which can guide the selection of targeted therapies. Moreover, liquid biopsies allow for the continuous monitoring of treatment effectiveness, helping doctors detect drug resistance early and adjust treatment plans accordingly. This precision medicine approach is transforming breast cancer care by offering more personalized, effective, and adaptive treatment options for patients.

What Role Do Liquid Biopsies Play in Early Detection and Monitoring of Breast Cancer?

Liquid biopsies play a crucial role in the early detection and monitoring of breast cancer by allowing clinicians to identify cancerous mutations and changes in tumor dynamics before they become detectable through imaging or physical examination. Early-stage breast cancer is often asymptomatic, and traditional diagnostic methods such as mammograms or tissue biopsies may miss small or early lesions. Liquid biopsies, however, can detect minute amounts of ctDNA shed by tumors into the bloodstream, providing a non-invasive method to identify cancer at an earlier stage. Early detection is critical for improving patient outcomes, as it increases the chances of successful treatment and reduces the risk of metastasis.

In addition to early detection, liquid biopsies are valuable for ongoing monitoring of breast cancer patients throughout their treatment journey. By tracking changes in ctDNA or CTC levels, clinicians can assess how well a patient is responding to therapy, detect minimal residual disease (MRD), and identify signs of relapse before traditional imaging methods reveal tumor growth. This ability to monitor cancer progression in real time allows for more dynamic and personalized treatment plans, improving overall survival rates and reducing the need for more invasive tests. As liquid biopsy technology continues to evolve, it is expected to become a standard tool in both early breast cancer detection and long-term patient monitoring.

How Are Liquid Biopsies Advancing Personalized Medicine in Breast Cancer?

Liquid biopsies are at the forefront of advancing personalized medicine in breast cancer by enabling a deeper understanding of the genetic and molecular landscape of each patient’s tumor. Through the analysis of ctDNA, liquid biopsies can identify specific genetic mutations, such as PIK3CA, ESR1, or BRCA1/2, which may influence how a patient responds to certain therapies. This information allows oncologists to tailor treatments to the individual patient’s unique cancer profile, selecting therapies that are most likely to be effective based on the presence of actionable mutations. For example, patients with HER2-positive breast cancer may benefit from targeted therapies like trastuzumab, while those with BRCA mutations may respond better to PARP inhibitors.

Liquid biopsies also help in identifying the emergence of treatment resistance, a common challenge in breast cancer management. Over time, cancer cells can acquire new mutations that allow them to evade the effects of chemotherapy or targeted therapies. Liquid biopsies enable clinicians to detect these resistance mutations early, allowing them to adjust treatment strategies and potentially switch to alternative therapies before the cancer progresses further. By providing real-time, molecular-level insights into the tumor’s evolution, liquid biopsies are empowering personalized medicine approaches that optimize treatment efficacy and minimize unnecessary side effects for breast cancer patients.

What Factors Are Driving the Growth of the Breast Cancer Liquid Biopsy Market?

The growth of the breast cancer liquid biopsy market is driven by several key factors, including the increasing demand for non-invasive diagnostic methods, advancements in precision medicine, and the rising incidence of breast cancer globally. As liquid biopsies offer a safer, less invasive alternative to tissue biopsies, more patients and healthcare providers are opting for this approach, particularly for patients who require frequent monitoring or those who are not candidates for traditional biopsies. The ability to perform repeated liquid biopsies over the course of treatment also allows for continuous monitoring of disease progression, helping to improve patient outcomes.

Technological advancements in liquid biopsy platforms, such as next-generation sequencing (NGS) and digital PCR, are enhancing the sensitivity and accuracy of these tests, further driving market adoption. The growing focus on personalized medicine and targeted therapies is another major factor fueling market growth, as liquid biopsies provide the molecular insights needed to tailor treatments to individual patients. Additionally, the increasing prevalence of breast cancer worldwide is creating a higher demand for early detection and monitoring tools, contributing to the expansion of the liquid biopsy market. As healthcare systems increasingly prioritize precision oncology and non-invasive diagnostics, the breast cancer liquid biopsy market is expected to experience sustained growth in the coming years.

Select Competitors (Total 34 Featured) -

  • Biodesix, Inc.
  • Bio-Rad Laboratories
  • Cynvenio Biosystems, Inc.
  • Fluxion Biosciences, Inc.
  • Genomic Health, Inc.
  • Guardant Health, Inc.
  • Illumina
  • Isogen Life Science B.V.
  • Menarini Silicon Biosystems
  • Myriad Genetics

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Global Economic Update
    • Breast Cancer Liquid Biopsy - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence of Breast Cancer Globally Drives Growth in the Breast Cancer Liquid Biopsy Market
    • Increasing Demand for Non-Invasive Diagnostics Expands the Addressable Market for Liquid Biopsies in Breast Cancer
    • Technological Advancements in Circulating Tumor DNA (ctDNA) and Cell-Free DNA (cfDNA) Testing Propel Innovation in Breast Cancer Liquid Biopsy
    • Growing Focus on Early Detection and Monitoring of Breast Cancer Strengthens the Business Case for Liquid Biopsy Solutions
    • Rising Adoption of Liquid Biopsies in Precision Medicine and Targeted Therapy Selection Fuels Market Growth
    • Increasing Use of Liquid Biopsies in Monitoring Treatment Response and Disease Recurrence Expands Applications in Breast Cancer Care
    • Technological Innovations in Next-Generation Sequencing (NGS) Propel Growth in High-Sensitivity Liquid Biopsy Platforms
    • Growing Focus on Minimally Invasive Cancer Diagnostics Expands the Market for Breast Cancer Liquid Biopsy
    • Rising Investment in Biomarker Discovery and Validation Strengthens Market Growth for Breast Cancer Liquid Biopsies
    • Growing Use of Liquid Biopsy for Companion Diagnostics in Breast Cancer Therapies Expands Market Reach
    • Technological Advancements in Exosome-Based and Protein Biomarker Detection Propel Growth in Breast Cancer Liquid Biopsies
    • Rising Focus on Liquid Biopsy for Real-Time Cancer Monitoring and Personalized Treatment Drives Adoption in Oncology
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Breast Cancer Liquid Biopsy Market Analysis of Annual Sales in US$ for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Breast Cancer Liquid Biopsy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Breast Cancer Liquid Biopsy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Prognostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Prognostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Prognostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Risk Assessment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Risk Assessment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Risk Assessment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Reagent Kits by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Reagent Kits by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Reagent Kits by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Instruments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 22: World 16-Year Perspective for Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Circulating Tumor Cells by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Circulating Tumor Cells by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 25: World 16-Year Perspective for Circulating Tumor Cells by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Extracellular Vesicles by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Extracellular Vesicles by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 28: World 16-Year Perspective for Extracellular Vesicles by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Circulating Tumor DNA by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Circulating Tumor DNA by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 31: World 16-Year Perspective for Circulating Tumor DNA by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Breast Cancer Liquid Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 32: USA Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Product & Service - Reagent Kits, Instruments and Services - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Breast Cancer Liquid Biopsy by Product & Service - Reagent Kits, Instruments and Services Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 34: USA 16-Year Perspective for Breast Cancer Liquid Biopsy by Product & Service - Percentage Breakdown of Value Sales for Reagent Kits, Instruments and Services for the Years 2014, 2024 & 2030
    • TABLE 35: USA Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Application - Diagnostics, Prognostics and Risk Assessment - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Breast Cancer Liquid Biopsy by Application - Diagnostics, Prognostics and Risk Assessment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 37: USA 16-Year Perspective for Breast Cancer Liquid Biopsy by Application - Percentage Breakdown of Value Sales for Diagnostics, Prognostics and Risk Assessment for the Years 2014, 2024 & 2030
    • TABLE 38: USA Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Circulating Biomarker - Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Breast Cancer Liquid Biopsy by Circulating Biomarker - Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 40: USA 16-Year Perspective for Breast Cancer Liquid Biopsy by Circulating Biomarker - Percentage Breakdown of Value Sales for Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Product & Service - Reagent Kits, Instruments and Services - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Breast Cancer Liquid Biopsy by Product & Service - Reagent Kits, Instruments and Services Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 43: Canada 16-Year Perspective for Breast Cancer Liquid Biopsy by Product & Service - Percentage Breakdown of Value Sales for Reagent Kits, Instruments and Services for the Years 2014, 2024 & 2030
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Application - Diagnostics, Prognostics and Risk Assessment - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Breast Cancer Liquid Biopsy by Application - Diagnostics, Prognostics and Risk Assessment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 46: Canada 16-Year Perspective for Breast Cancer Liquid Biopsy by Application - Percentage Breakdown of Value Sales for Diagnostics, Prognostics and Risk Assessment for the Years 2014, 2024 & 2030
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Circulating Biomarker - Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Breast Cancer Liquid Biopsy by Circulating Biomarker - Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 49: Canada 16-Year Perspective for Breast Cancer Liquid Biopsy by Circulating Biomarker - Percentage Breakdown of Value Sales for Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA for the Years 2014, 2024 & 2030
  • JAPAN
    • Breast Cancer Liquid Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Product & Service - Reagent Kits, Instruments and Services - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Japan Historic Review for Breast Cancer Liquid Biopsy by Product & Service - Reagent Kits, Instruments and Services Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 52: Japan 16-Year Perspective for Breast Cancer Liquid Biopsy by Product & Service - Percentage Breakdown of Value Sales for Reagent Kits, Instruments and Services for the Years 2014, 2024 & 2030
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Application - Diagnostics, Prognostics and Risk Assessment - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for Breast Cancer Liquid Biopsy by Application - Diagnostics, Prognostics and Risk Assessment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 55: Japan 16-Year Perspective for Breast Cancer Liquid Biopsy by Application - Percentage Breakdown of Value Sales for Diagnostics, Prognostics and Risk Assessment for the Years 2014, 2024 & 2030
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Circulating Biomarker - Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for Breast Cancer Liquid Biopsy by Circulating Biomarker - Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 58: Japan 16-Year Perspective for Breast Cancer Liquid Biopsy by Circulating Biomarker - Percentage Breakdown of Value Sales for Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA for the Years 2014, 2024 & 2030
  • CHINA
    • Breast Cancer Liquid Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 59: China Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Product & Service - Reagent Kits, Instruments and Services - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 60: China Historic Review for Breast Cancer Liquid Biopsy by Product & Service - Reagent Kits, Instruments and Services Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 61: China 16-Year Perspective for Breast Cancer Liquid Biopsy by Product & Service - Percentage Breakdown of Value Sales for Reagent Kits, Instruments and Services for the Years 2014, 2024 & 2030
    • TABLE 62: China Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Application - Diagnostics, Prognostics and Risk Assessment - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 63: China Historic Review for Breast Cancer Liquid Biopsy by Application - Diagnostics, Prognostics and Risk Assessment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 64: China 16-Year Perspective for Breast Cancer Liquid Biopsy by Application - Percentage Breakdown of Value Sales for Diagnostics, Prognostics and Risk Assessment for the Years 2014, 2024 & 2030
    • TABLE 65: China Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Circulating Biomarker - Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 66: China Historic Review for Breast Cancer Liquid Biopsy by Circulating Biomarker - Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 67: China 16-Year Perspective for Breast Cancer Liquid Biopsy by Circulating Biomarker - Percentage Breakdown of Value Sales for Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA for the Years 2014, 2024 & 2030
  • EUROPE
    • Breast Cancer Liquid Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
    • TABLE 69: Europe Historic Review for Breast Cancer Liquid Biopsy by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 70: Europe 16-Year Perspective for Breast Cancer Liquid Biopsy by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Product & Service - Reagent Kits, Instruments and Services - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Breast Cancer Liquid Biopsy by Product & Service - Reagent Kits, Instruments and Services Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 73: Europe 16-Year Perspective for Breast Cancer Liquid Biopsy by Product & Service - Percentage Breakdown of Value Sales for Reagent Kits, Instruments and Services for the Years 2014, 2024 & 2030
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Application - Diagnostics, Prognostics and Risk Assessment - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Breast Cancer Liquid Biopsy by Application - Diagnostics, Prognostics and Risk Assessment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 76: Europe 16-Year Perspective for Breast Cancer Liquid Biopsy by Application - Percentage Breakdown of Value Sales for Diagnostics, Prognostics and Risk Assessment for the Years 2014, 2024 & 2030
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Circulating Biomarker - Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Breast Cancer Liquid Biopsy by Circulating Biomarker - Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 79: Europe 16-Year Perspective for Breast Cancer Liquid Biopsy by Circulating Biomarker - Percentage Breakdown of Value Sales for Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA for the Years 2014, 2024 & 2030
  • FRANCE
    • Breast Cancer Liquid Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 80: France Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Product & Service - Reagent Kits, Instruments and Services - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 81: France Historic Review for Breast Cancer Liquid Biopsy by Product & Service - Reagent Kits, Instruments and Services Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 82: France 16-Year Perspective for Breast Cancer Liquid Biopsy by Product & Service - Percentage Breakdown of Value Sales for Reagent Kits, Instruments and Services for the Years 2014, 2024 & 2030
    • TABLE 83: France Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Application - Diagnostics, Prognostics and Risk Assessment - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 84: France Historic Review for Breast Cancer Liquid Biopsy by Application - Diagnostics, Prognostics and Risk Assessment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 85: France 16-Year Perspective for Breast Cancer Liquid Biopsy by Application - Percentage Breakdown of Value Sales for Diagnostics, Prognostics and Risk Assessment for the Years 2014, 2024 & 2030
    • TABLE 86: France Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Circulating Biomarker - Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 87: France Historic Review for Breast Cancer Liquid Biopsy by Circulating Biomarker - Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 88: France 16-Year Perspective for Breast Cancer Liquid Biopsy by Circulating Biomarker - Percentage Breakdown of Value Sales for Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA for the Years 2014, 2024 & 2030
  • GERMANY
    • Breast Cancer Liquid Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 89: Germany Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Product & Service - Reagent Kits, Instruments and Services - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Germany Historic Review for Breast Cancer Liquid Biopsy by Product & Service - Reagent Kits, Instruments and Services Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 91: Germany 16-Year Perspective for Breast Cancer Liquid Biopsy by Product & Service - Percentage Breakdown of Value Sales for Reagent Kits, Instruments and Services for the Years 2014, 2024 & 2030
    • TABLE 92: Germany Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Application - Diagnostics, Prognostics and Risk Assessment - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Germany Historic Review for Breast Cancer Liquid Biopsy by Application - Diagnostics, Prognostics and Risk Assessment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 94: Germany 16-Year Perspective for Breast Cancer Liquid Biopsy by Application - Percentage Breakdown of Value Sales for Diagnostics, Prognostics and Risk Assessment for the Years 2014, 2024 & 2030
    • TABLE 95: Germany Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Circulating Biomarker - Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Germany Historic Review for Breast Cancer Liquid Biopsy by Circulating Biomarker - Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 97: Germany 16-Year Perspective for Breast Cancer Liquid Biopsy by Circulating Biomarker - Percentage Breakdown of Value Sales for Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 98: Italy Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Product & Service - Reagent Kits, Instruments and Services - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Italy Historic Review for Breast Cancer Liquid Biopsy by Product & Service - Reagent Kits, Instruments and Services Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 100: Italy 16-Year Perspective for Breast Cancer Liquid Biopsy by Product & Service - Percentage Breakdown of Value Sales for Reagent Kits, Instruments and Services for the Years 2014, 2024 & 2030
    • TABLE 101: Italy Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Application - Diagnostics, Prognostics and Risk Assessment - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Italy Historic Review for Breast Cancer Liquid Biopsy by Application - Diagnostics, Prognostics and Risk Assessment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 103: Italy 16-Year Perspective for Breast Cancer Liquid Biopsy by Application - Percentage Breakdown of Value Sales for Diagnostics, Prognostics and Risk Assessment for the Years 2014, 2024 & 2030
    • TABLE 104: Italy Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Circulating Biomarker - Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Italy Historic Review for Breast Cancer Liquid Biopsy by Circulating Biomarker - Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 106: Italy 16-Year Perspective for Breast Cancer Liquid Biopsy by Circulating Biomarker - Percentage Breakdown of Value Sales for Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Breast Cancer Liquid Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 107: UK Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Product & Service - Reagent Kits, Instruments and Services - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 108: UK Historic Review for Breast Cancer Liquid Biopsy by Product & Service - Reagent Kits, Instruments and Services Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 109: UK 16-Year Perspective for Breast Cancer Liquid Biopsy by Product & Service - Percentage Breakdown of Value Sales for Reagent Kits, Instruments and Services for the Years 2014, 2024 & 2030
    • TABLE 110: UK Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Application - Diagnostics, Prognostics and Risk Assessment - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 111: UK Historic Review for Breast Cancer Liquid Biopsy by Application - Diagnostics, Prognostics and Risk Assessment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 112: UK 16-Year Perspective for Breast Cancer Liquid Biopsy by Application - Percentage Breakdown of Value Sales for Diagnostics, Prognostics and Risk Assessment for the Years 2014, 2024 & 2030
    • TABLE 113: UK Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Circulating Biomarker - Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 114: UK Historic Review for Breast Cancer Liquid Biopsy by Circulating Biomarker - Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 115: UK 16-Year Perspective for Breast Cancer Liquid Biopsy by Circulating Biomarker - Percentage Breakdown of Value Sales for Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 116: Rest of Europe Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Product & Service - Reagent Kits, Instruments and Services - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 117: Rest of Europe Historic Review for Breast Cancer Liquid Biopsy by Product & Service - Reagent Kits, Instruments and Services Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 118: Rest of Europe 16-Year Perspective for Breast Cancer Liquid Biopsy by Product & Service - Percentage Breakdown of Value Sales for Reagent Kits, Instruments and Services for the Years 2014, 2024 & 2030
    • TABLE 119: Rest of Europe Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Application - Diagnostics, Prognostics and Risk Assessment - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 120: Rest of Europe Historic Review for Breast Cancer Liquid Biopsy by Application - Diagnostics, Prognostics and Risk Assessment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 121: Rest of Europe 16-Year Perspective for Breast Cancer Liquid Biopsy by Application - Percentage Breakdown of Value Sales for Diagnostics, Prognostics and Risk Assessment for the Years 2014, 2024 & 2030
    • TABLE 122: Rest of Europe Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Circulating Biomarker - Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 123: Rest of Europe Historic Review for Breast Cancer Liquid Biopsy by Circulating Biomarker - Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 124: Rest of Europe 16-Year Perspective for Breast Cancer Liquid Biopsy by Circulating Biomarker - Percentage Breakdown of Value Sales for Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Breast Cancer Liquid Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 125: Asia-Pacific Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Product & Service - Reagent Kits, Instruments and Services - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 126: Asia-Pacific Historic Review for Breast Cancer Liquid Biopsy by Product & Service - Reagent Kits, Instruments and Services Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 127: Asia-Pacific 16-Year Perspective for Breast Cancer Liquid Biopsy by Product & Service - Percentage Breakdown of Value Sales for Reagent Kits, Instruments and Services for the Years 2014, 2024 & 2030
    • TABLE 128: Asia-Pacific Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Application - Diagnostics, Prognostics and Risk Assessment - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 129: Asia-Pacific Historic Review for Breast Cancer Liquid Biopsy by Application - Diagnostics, Prognostics and Risk Assessment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 130: Asia-Pacific 16-Year Perspective for Breast Cancer Liquid Biopsy by Application - Percentage Breakdown of Value Sales for Diagnostics, Prognostics and Risk Assessment for the Years 2014, 2024 & 2030
    • TABLE 131: Asia-Pacific Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Circulating Biomarker - Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 132: Asia-Pacific Historic Review for Breast Cancer Liquid Biopsy by Circulating Biomarker - Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 133: Asia-Pacific 16-Year Perspective for Breast Cancer Liquid Biopsy by Circulating Biomarker - Percentage Breakdown of Value Sales for Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA for the Years 2014, 2024 & 2030
  • REST OF WORLD
    • TABLE 134: Rest of World Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Product & Service - Reagent Kits, Instruments and Services - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Rest of World Historic Review for Breast Cancer Liquid Biopsy by Product & Service - Reagent Kits, Instruments and Services Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 136: Rest of World 16-Year Perspective for Breast Cancer Liquid Biopsy by Product & Service - Percentage Breakdown of Value Sales for Reagent Kits, Instruments and Services for the Years 2014, 2024 & 2030
    • TABLE 137: Rest of World Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Application - Diagnostics, Prognostics and Risk Assessment - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 138: Rest of World Historic Review for Breast Cancer Liquid Biopsy by Application - Diagnostics, Prognostics and Risk Assessment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 139: Rest of World 16-Year Perspective for Breast Cancer Liquid Biopsy by Application - Percentage Breakdown of Value Sales for Diagnostics, Prognostics and Risk Assessment for the Years 2014, 2024 & 2030
    • TABLE 140: Rest of World Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Circulating Biomarker - Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Rest of World Historic Review for Breast Cancer Liquid Biopsy by Circulating Biomarker - Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 142: Rest of World 16-Year Perspective for Breast Cancer Liquid Biopsy by Circulating Biomarker - Percentage Breakdown of Value Sales for Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA for the Years 2014, 2024 & 2030

IV. COMPETITION